Dr. Mark Sullivan holds undergraduate degrees in microbiology and molecular biology through Washington State University and advanced degrees of Doctor of Medicine and Master of Public Health both through the University of Washington. He is a board certified physician in three specialties of Internal Medicine, Critical Care Medicine, and Occupational/Environmental Medicine with special interest in toxic exposure assessment and treatment. Dr. Sullivan completed his MPH research thesis on the association between transition metal components of < 2.5 micron particulate matter (PM 2.5) and lung function and density as potentially relates to chronic obstructive pulmonary disease (COPD) prevalence. Past research experience includes identifying the structure of the working genome of the Human Foamy Retrovirus at Fred Hutchinson Cancer Research Center, and helping to identify the Alzheimer’s and Werner’s disease gene locus at the University of Washington.
Jared Hooks, PhD
Jared majored in both biochemistry and genetics while attending Texas A&M University for his bachelor’s degree. During this time, he performed research utilizing peptide chemistry, cloning and protein expression, and native chemical ligation to synthesize novel semi-synthetic protein constructs for use as intracellular probes. Jared also holds a PhD in cancer biology from the University of Texas Southwestern Graduate School for Biomedical Sciences. His dissertation work ranged from developing and characterizing a cancer specific, heterodimeric, dual-targeted peptidomimetic compound, to interrogating the TGFβ-dependent regulation of the tumor suppressor ARF in human cancer cells. While performing his dissertation research, he moonlighted in science policy as an Archer Center Fellow, and in the startup realm as an intern for the Dallas-based accelerator, Health Wildcatters.
Sascha C. T. Nicklisch, PhD
Sascha has more than 12 years of international and cross-disciplinary research experience in academia and industry. He majored in biological sciences at the University of Cologne, Germany, and received a PhD in biochemistry from the Institute of Biochemistry at Cologne University. Prior to joining UC San Diego in 2012, he worked a year as Research Associate in the Experimental Physics Department at the University of Osnabrück, Germany, and another two years as a Postdoctoral Research Fellow at UC Santa Barbara. His expertise is in expression, purification and structure-function analysis of diverse soluble proteins and membrane transporters, pharmaceutical and organic chemical interactions with MDR-type ABC-transporters, and their application in tool development for chemical bioaccumulation and bio-monitoring. Besides consulting for August Therapeutics, Sascha is currently an instructor for Pollution, Environment and Human Health (SIO189) and Recombinant DNA Techniques (BIMM101) at UC San Diego and a Staff Scientist at Scripps Institution of Oceanography, developing field-deployable pollutant sensors based on single domain antibodies for commercialization. Sascha has consulted for local and statewide projects on human and environmental toxicology, including the City of San Diego, UC Santa Barbara, Portland State University, and for the California Council on Science and Technology (CCST). His research has been funded by government agencies, private donors and foundations. Sascha has published 14 peer-reviewed articles, including his key study in Science Advances that was granted the 2017 Best Postdoctoral Publication Award from the Society of Toxicology.
Anthony Farina, PhD
Anthony received his BS in biochemistry from the University of California, Riverside and a PhD in biochemistry and chemistry from the University of California, San Diego and was a post doctoral scholar at the David Geffen School of Medicine at the Univeristy of California, Los Angeles. His area of expertise is focused around protein chemistry and synthetic biology. In addition to consulting for August Therapeutics, he is currently the CSO of Librede, Inc. a synthetic biology company focused on producing cannabidiol in microorganisms and has the first issued patent around complete biosynthesis of CBD in yeast.
Lecya is a graduate from UC Santa Cruz with a degree in molecular and cell developmental biology. While in Santa Cruz, she focused her studies in cancer genomics and genome sequencing. She also participated in the UC Santa Cruz Genomics Institute with the Treehouse Childhood Initiative analyzing cancer data, focusing on creating gene expression models to identify tumors that were driven by the same molecular pathways. Her aim as a growing scientist is to develop more effective and less toxic therapies.